Grants and Contributions:
Title:
SOR-C13 for COVID-19 Treatment
Agreement Number:
958701
Agreement Value:
$66,978.00
Agreement Date:
Sep 15, 2020 - Mar 31, 2021
Description:
The project includes preclinical studies required to advance SOR-C13, a clinical stage oncology drug, for the prevention and/or treatment of COVID-19 into clinical trials.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Moncton, New Brunswick, CA E1C 4W7
Reference Number:
172-2020-2021-Q3-958701
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
826461147
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 2 time(s). The end date of this agreements has been modified by 61 days. The total amended value is -67,704 dollars.
Amendment Date
Mar 9, 2021
Recipient's Operating Name:
Soricimed Biopharma Inc.
Recipient's Legal Name:
Soricimed Biopharma Inc.
Federal Riding Name:
Moncton--Riverview--Dieppe
Federal Riding Number:
13007
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
541710
Amendments: